Related Experiment Videos
The surgery of extracranial vascular occlusive disease
Insights
Surgical therapy effectively treats symptomatic carotid stenosis (70-99%). Future trials will clarify treatment for asymptomatic carotid artery stenosis, aided by new screening technologies.
Area of Science:
- Vascular Surgery
- Neurology
- Cardiology
Background:
- Extracranial cerebrovascular disease management is evolving.
- Surgical therapy is an established treatment for symptomatic carotid disease.
- Major clinical trials provide strong evidence for surgical intervention.
Purpose of the Study:
- To review the current state of extracranial cerebrovascular disease treatment.
- To highlight the role of surgical therapy in symptomatic carotid stenosis.
- To discuss the implications of upcoming trials for asymptomatic disease.
Main Methods:
- Review of major clinical trials, including NASCET and ECST.
- Discussion of emerging diagnostic technologies like duplex scanning and MRA.
- Consideration of future research directions and data monitoring.
Main Results:
- NASCET and ECST strongly endorse surgical therapy for 70-99% symptomatic carotid stenosis.
- Results from ACAS and VA trials are pending for asymptomatic disease.
- New technologies will enhance screening in aging populations.
Conclusions:
- Surgical intervention is well-supported for symptomatic carotid stenosis.
- Further research is needed to address controversies in asymptomatic carotid artery stenosis.
- In-hospital registries are crucial for monitoring outcomes in vascular surgery.
Abstract:
The task of reducing the entire field of extracranial cerebrovascular disease to a review of this brevity may be Sisyphean. The surgical therapy of extracranial cerebrovascular disease has developed into an established mode with excellent support from major clinical trials. In regards to symptomatic carotid disease, the North American Symptomatic Carotid Endarterectomy Trial (NASCET), and the European Carotid Surgery Trial (ECST) have both strongly endorsed surgical therapy in patients with 70 to 99 percent stenosis. In the near future, results from two major asymptomatic trials, Asymptomatic Carotid Artery Stenosis Study (ACAS) and Asymptomatic Carotid Stenosis Veterans Administration Study (VA No. 167) should be available to illuminate the controversies of asymptomatic disease. Undoubtedly, new technologies such as duplex scanning and magnetic resonance angiography will have greater roles in the screening of our rapidly aging population for these diseases. Finally, vascular surgery, a major consumer of high technology in hospital resources, will be continually scrutinized by the regulating agencies in the future. It will behoove all interested parties to pursue in hospital registries for monitoring of outcome data in this evolving field.